{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T20:58:57Z","timestamp":1769115537463,"version":"3.49.0"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,11,2]],"date-time":"2017-11-02T00:00:00Z","timestamp":1509580800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s00223-017-0351-7","type":"journal-article","created":{"date-parts":[[2017,11,2]],"date-time":"2017-11-02T19:09:35Z","timestamp":1509649775000},"page":"196-209","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["New agents in the Treatment of Myeloma Bone Disease"],"prefix":"10.1007","volume":"102","author":[{"given":"Elizabeth S.","family":"Ring","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle A.","family":"Lawson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John A.","family":"Snowden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid","family":"Jolley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew D.","family":"Chantry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,11,2]]},"reference":[{"key":"351_CR1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4137\/CGM.S16817","volume":"7","author":"A Hameed","year":"2014","unstructured":"Hameed A, Brady JJ, Dowling P, Clynes M, Gorman P (2014) Bone disease in multiple myeloma: pathophysiology and management. Cancer Growth Metastasis 7:33\u201342","journal-title":"Cancer Growth Metastasis"},{"key":"351_CR2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66:7\u201330","journal-title":"CA Cancer J Clin"},{"key":"351_CR3","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.pbiomolbio.2016.08.003","volume":"122","author":"H Xi","year":"2016","unstructured":"Xi H, An R, Li L, Wang G, Tao Y, Gao L (2016) Myeloma bone disease: progress in pathogenesis. Prog Biophys Mol Biol 122:149\u2013155","journal-title":"Prog Biophys Mol Biol"},{"key":"351_CR4","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJM199706053362307","volume":"336","author":"R Bataille","year":"1997","unstructured":"Bataille R, Harousseau J-L (1997) Multiple myeloma. N Engl J Med 336:1657\u20131664","journal-title":"N Engl J Med"},{"key":"351_CR5","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/bmb\/ldu016","volume":"111","author":"RE Walker","year":"2014","unstructured":"Walker RE, Lawson MA, Buckle CH, Snowden JA, Chantry AD (2014) Myeloma bone disease: pathogenesis, current treatments and future targets. Br Med Bull 111:117\u2013138","journal-title":"Br Med Bull"},{"key":"351_CR6","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1002\/jcp.25351","volume":"231","author":"R Silbermann","year":"2016","unstructured":"Silbermann R, Roodman GD (2016) Current controversies in the management of myeloma bone disease. J Cell Physiol 231:2374\u20132379","journal-title":"J Cell Physiol"},{"key":"351_CR7","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","volume":"28","author":"SK Kumar","year":"2014","unstructured":"Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, Kapoor P, Dingli D, Hayman SR, Leung N (2014) Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 28:1122\u20131128","journal-title":"Leukemia"},{"key":"351_CR8","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.bone.2016.07.007","volume":"91","author":"JS Nyman","year":"2016","unstructured":"Nyman JS, Merkel AR, Uppuganti S, Nayak B, Rowland B, Makowski AJ, Oyajobi BO, Sterling JA (2016) Combined treatment with a transforming growth factor beta inhibitor (1D11) and bortezomib improves bone architecture in a mouse model of myeloma-induced bone disease. Bone 91:81\u201391","journal-title":"Bone"},{"key":"351_CR9","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMoa030847","volume":"349","author":"E Tian","year":"2003","unstructured":"Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JDJ (2003) The role of the Wnt-Signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349:2483\u20132494","journal-title":"N Engl J Med"},{"key":"351_CR10","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1182\/blood.V126.23.119.119","volume":"126","author":"MR Reagan","year":"2015","unstructured":"Reagan MR, McDonald M, Terry R, Pettitt J, Le L, Mohanty S, Kneissel M, Kramer I, Brooks D, Bouxsein M, Rosen CJ, Ghobrial IM, Croucher P (2015) Anti-sclerostin treatment prevents multiple myeloma induced bone loss and reduces tumor burden. Blood 126:119\u2013119","journal-title":"Blood"},{"key":"351_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jcb.20774","volume":"98","author":"JP Stewart","year":"2006","unstructured":"Stewart JP, Shaughnessy JD (2006) Role of osteoblast suppression in multiple myeloma. J Cell Biochem 98:1\u201313","journal-title":"J Cell Biochem"},{"key":"351_CR12","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.devcel.2005.03.016","volume":"8","author":"TF Day","year":"2005","unstructured":"Day TF, Guo X, Garrett-Beal L, Yang Y (2005) Wnt\/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell 8:739\u2013750","journal-title":"Dev Cell"},{"key":"351_CR13","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1634\/stemcells.2005-0220","volume":"24","author":"WG Gunn","year":"2006","unstructured":"Gunn WG, Conley A, Deininger L, Olson SD, Prockop DJ, Gregory CA (2006) A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells 24:986\u2013991","journal-title":"Stem Cells"},{"key":"351_CR14","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1056\/NEJM197411142912001","volume":"291","author":"GR Mundy","year":"1974","unstructured":"Mundy GR, Raisz LG, Cooper RA, Schechter GP, Salmon SE (1974) Evidence for the secretion of an osteoclast stimulating factor in myeloma. N Engl J Med 291:1041\u20131046","journal-title":"N Engl J Med"},{"key":"351_CR15","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1172\/JCI115305","volume":"88","author":"R Bataille","year":"1991","unstructured":"Bataille R, Chappard D, Marcelli C, Dessauw P, Baldet P, Sany J, Alexandre C (1991) Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J Clin Invest 88:62\u201366","journal-title":"J Clin Invest"},{"key":"351_CR16","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1034\/j.1600-0609.2000.90074.x","volume":"64","author":"N Abildgaard","year":"2000","unstructured":"Abildgaard N, Glerup H, Rungby J, Bendix-Hansen K, Kassem M, Brixen K, Heickendorff L, Nielsen JL, Eriksen EF (2000) Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma. Eur J Haematol 64:121\u2013129","journal-title":"Eur J Haematol"},{"key":"351_CR17","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1182\/blood-2007-11-124164","volume":"112","author":"X Li","year":"2008","unstructured":"Li X, Pennisi A, Yaccoby S (2008) Role of decorin in the antimyeloma effects of osteoblasts. Blood 112:159\u2013168","journal-title":"Blood"},{"key":"351_CR18","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.exphem.2009.11.009","volume":"38","author":"K Todoerti","year":"2010","unstructured":"Todoerti K, Lisignoli G, Storti P, Agnelli L, Novara F, Manferdini C, Codeluppi K, Colla S, Crugnola M, Abeltino M, Bolzoni M, Sgobba V, Facchini A, Lambertenghi-Deliliers G, Zuffardi O, Rizzoli V, Neri A, Giuliani N (2010) Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease. Exp Hematol 38:141\u2013153","journal-title":"Exp Hematol"},{"key":"351_CR19","doi-asserted-by":"crossref","first-page":"e0137552","DOI":"10.1371\/journal.pone.0137552","volume":"10","author":"SY Huang","year":"2015","unstructured":"Huang SY, Lin HH, Yao M, Tang JL, Wu SJ, Hou HA, Chou WC, Chou SC, Hsu SC, Ko BS, Lu HY, Tsay W, Tien HF (2015) Higher decorin levels in bone marrow plasma are associated with superior treatment response to novel agent-based induction in patients with newly diagnosed myeloma\u2014a retrospective study. PLoS ONE 10:e0137552","journal-title":"PLoS ONE"},{"key":"351_CR20","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1182\/blood-2014-02-558007","volume":"124","author":"MR Reagan","year":"2014","unstructured":"Reagan MR, Mishima Y, Glavey SV, Zhang Y, Manier S, Lu ZN, Memarzadeh M, Sacco A, Aljawai Y, Shi J, Tai YT, Ready JE, Kaplan DL, Roccaro AM, Ghobrial IM (2014) Investigating osteogenic differentiation in multiple myeloma using a novel 3D bone marrow niche model. Blood 124:3250\u20133259","journal-title":"Blood"},{"key":"351_CR21","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1182\/blood.V98.13.3527","volume":"98","author":"N Giuliani","year":"2001","unstructured":"Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barill\u00e9 S (2001) Myeloma cells induce imbalance in the osteoprotegerin\/osteoprotegerin ligand system in the human bone marrow environment. Blood 98:3527\u20133533","journal-title":"Blood"},{"key":"351_CR22","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1182\/blood.V98.13.3534","volume":"98","author":"PI Croucher","year":"2001","unstructured":"Croucher PI, Shipman CM, Lippitt J, Perry M, Asosingh K, Hijzen A, Brabbs AC, van Beek EJ, Holen I, Skerry TM, Dunstan CR, Russell GR, Van Camp B, Vanderkerken K (2001) Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 98:3534\u20133540","journal-title":"Blood"},{"key":"351_CR23","doi-asserted-by":"crossref","first-page":"6270s","DOI":"10.1158\/1078-0432.CCR-06-0845","volume":"12","author":"GD Roodman","year":"2006","unstructured":"Roodman GD (2006) New potential targets for treating myeloma bone disease. Clin Cancer Res 12:6270s\u20136273s","journal-title":"Clin Cancer Res"},{"key":"351_CR24","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/blood-2008-11-191577","volume":"114","author":"M Fulciniti","year":"2009","unstructured":"Fulciniti M, Tassone P, Hideshima T, Vallet S, Nanjappa P, Ettenberg SA, Shen Z, Patel N, Y-t Tai, Chauhan D (2009) Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 114:371\u2013379","journal-title":"Blood"},{"key":"351_CR25","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1182\/blood-2014-11-568881","volume":"125","author":"G Bianchi","year":"2015","unstructured":"Bianchi G, Munshi NC (2015) Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood 125:3049\u20133058","journal-title":"Blood"},{"key":"351_CR26","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.leukres.2014.02.010","volume":"38","author":"X-T Wang","year":"2014","unstructured":"Wang X-T, He Y-C, Zhou S-Y, J-z Jiang, Huang Y-M, Liang Y-Z, Lai Y-R (2014) Bone marrow plasma macrophage inflammatory protein protein-1 alpha (MIP-1 alpha) and sclerostin in multiple myeloma: relationship with bone disease and clinical characteristics. Leuk Res 38:525\u2013531","journal-title":"Leuk Res"},{"key":"351_CR27","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1182\/blood-2003-06-1992","volume":"103","author":"JW Lee","year":"2004","unstructured":"Lee JW, Chung HY, Ehrlich LA, Jelinek DF, Callander NS, Roodman GD, Choi SJ (2004) IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood 103:2308\u20132315","journal-title":"Blood"},{"key":"351_CR28","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1158\/1078-0432.CCR-06-2258","volume":"13","author":"Y Tanaka","year":"2007","unstructured":"Tanaka Y, Abe M, Hiasa M, Oda A, Amou H, Nakano A, Takeuchi K, Kitazoe K, Kido S, Inoue D, Moriyama K, Hashimoto T, Ozaki S, Matsumoto T (2007) Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin. Clin Cancer Res 13:816\u2013823","journal-title":"Clin Cancer Res"},{"key":"351_CR29","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.bone.2013.02.022","volume":"54","author":"TA Burgers","year":"2013","unstructured":"Burgers TA, Williams BO (2013) Regulation of Wnt\/\u03b2-catenin signaling within and from osteocytes. Bone 54:244\u2013249","journal-title":"Bone"},{"key":"351_CR30","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1182\/blood-2017-03-773341","volume":"129","author":"MM McDonald","year":"2017","unstructured":"McDonald MM, Reagan MR, Youlten SE, Mohanty ST, Seckinger A, Terry RL, Pettitt JA, Simic MK, Cheng TL, Morse A, Le LMT, Abi-Hanna D, Kramer I, Falank C, Fairfield H, Ghobrial IM, Baldock PA, Little DG, Kneissel M, Vanderkerken K, Bassett JHD, Williams GR, Oyajobi BO, Hose D, Phan TG, Croucher PI (2017) Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma. Blood 129:3452\u20133464","journal-title":"Blood"},{"key":"351_CR31","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1182\/blood-2014-12-613968","volume":"125","author":"TN Trotter","year":"2015","unstructured":"Trotter TN, Li M, Pan Q, Peker D, Rowan PD, Li J, Zhan F, Suva LJ, Javed A, Yang Y (2015) Myeloma cell-derived Runx2 promotes myeloma progression in bone. Blood 125:3598\u20133608","journal-title":"Blood"},{"key":"351_CR32","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1182\/blood-2006-05-026112","volume":"108","author":"N Giuliani","year":"2006","unstructured":"Giuliani N, Rizzoli V, Roodman GD (2006) Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood 108:3992\u20133996","journal-title":"Blood"},{"key":"351_CR33","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1182\/blood-2004-12-4986","volume":"106","author":"N Giuliani","year":"2005","unstructured":"Giuliani N (2005) Myeloma cells block RUNX2\/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 106:2472\u20132483","journal-title":"Blood"},{"key":"351_CR34","doi-asserted-by":"crossref","first-page":"289458","DOI":"10.1155\/2013\/289458","volume":"2013","author":"A Oranger","year":"2013","unstructured":"Oranger A, Carbone C, Izzo M, Grano M (2013) Cellular mechanisms of multiple myeloma bone disease. Clin Dev Immunol 2013:289458","journal-title":"Clin Dev Immunol"},{"key":"351_CR35","first-page":"76","volume":"14","author":"EC Papadopoulou","year":"2010","unstructured":"Papadopoulou EC, Batzios SP, Dimitriadou M, Perifanis V, Garipidou V (2010) Multiple myeloma and bone disease: pathogenesis and current therapeutic approaches. Hippokratia 14:76\u201381","journal-title":"Hippokratia"},{"key":"351_CR36","doi-asserted-by":"crossref","unstructured":"Mitsiades CS, McMillin DW, Klippel S, Hideshima T, Chauhan D, Richardson PG, Munshi NC, Anderson KC (2007) The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. Hematol Oncol Clin N Am 21:1007\u20131034, vii\u2013viii","DOI":"10.1016\/j.hoc.2007.08.007"},{"key":"351_CR37","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1182\/blood-2011-05-353300","volume":"119","author":"G Xu","year":"2012","unstructured":"Xu G, Liu K, Anderson J, Patrene K, Lentzsch S, Roodman GD, Ouyang H (2012) Expression of XBP1s in bone marrow stromal cells is critical for myeloma cell growth and osteoclast formation. Blood 119:4205\u20134214","journal-title":"Blood"},{"key":"351_CR38","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/bonekey.2012.135","volume":"1","author":"DL Galson","year":"2012","unstructured":"Galson DL, Silbermann R, Roodman GD (2012) Mechanisms of multiple myeloma bone disease. Bonekey Rep 1:135","journal-title":"Bonekey Rep"},{"key":"351_CR39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0378-1119(03)00841-2","volume":"321","author":"MS Nanes","year":"2003","unstructured":"Nanes MS (2003) Tumor necrosis factor-alpha: molecular and cellular mechanisms in skeletal pathology. Gene 321:1\u201315","journal-title":"Gene"},{"key":"351_CR40","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1046\/j.1365-2141.1997.1042920.x","volume":"97","author":"T Diamond","year":"1997","unstructured":"Diamond T, Levy S, Day P, Barbagallo S, Manoharan A, Kwan YK (1997) Biochemical, histomorphometric and densitometric changes in patients with multiple myeloma: effects of glucocorticoid therapy and disease activity. Br J Haematol 97:641\u2013648","journal-title":"Br J Haematol"},{"key":"351_CR41","first-page":"104546","volume":"2013","author":"P Tosi","year":"2013","unstructured":"Tosi P (2013) Diagnosis and treatment of bone disease in multiple myeloma: spotlight on spinal involvement. Scientifica (Cairo) 2013:104546","journal-title":"Scientifica (Cairo)"},{"key":"351_CR42","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1188\/08.CJON.S1.53-62","volume":"12","author":"B Faiman","year":"2008","unstructured":"Faiman B, Bilotti E, Mangan PA, Rogers K, Board INL (2008) Steroid-associated side effects in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board. Clin J Oncol Nurs 12:53\u201363","journal-title":"Clin J Oncol Nurs"},{"key":"351_CR43","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","volume":"375","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Komarnicki M, Suzuki K, Plesner T, Yoon SS, Ben Yehuda D, Richardson PG, Goldschmidt H, Reece D, Lisby S, Khokhar NZ, O\u2019Rourke L, Chiu C, Qin X, Guckert M, Ahmadi T, Moreau P, Investigators P (2016) Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 375:1319\u20131331","journal-title":"N Engl J Med"},{"key":"351_CR44","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/SPC.0000000000000090","volume":"8","author":"J Delgado-Calle","year":"2014","unstructured":"Delgado-Calle J, Bellido T, Roodman GD (2014) Role of osteocytes in multiple myeloma bone disease. Curr Opin Support Palliat Care 8:407\u2013413","journal-title":"Curr Opin Support Palliat Care"},{"key":"351_CR45","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/leu.2011.381","volume":"26","author":"N Giuliani","year":"2012","unstructured":"Giuliani N, Ferretti M, Bolzoni M, Storti P, Lazzaretti M, Dalla Palma B, Bonomini S, Martella E, Agnelli L, Neri A, Ceccarelli F, Palumbo C (2012) Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation. Leukemia 26:1391\u20131401","journal-title":"Leukemia"},{"key":"351_CR46","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.cytogfr.2005.02.005","volume":"16","author":"RL Bezooijen van","year":"2005","unstructured":"van Bezooijen RL, ten Dijke P, Papapoulos SE, L\u00f6wik CW (2005) SOST\/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev 16:319\u2013327","journal-title":"Cytokine Growth Factor Rev"},{"key":"351_CR47","doi-asserted-by":"crossref","first-page":"6030","DOI":"10.1158\/1078-0432.CCR-12-3211","volume":"19","author":"GJ Morgan","year":"2013","unstructured":"Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Cook G, Drayson MT, Owen RG, Ross FM, Jackson GH, Child JA (2013) Long-term follow-up of MRC myeloma IX trial: survival outcomes with bisphosphonate and thalidomide treatment. Clin Cancer Res 19:6030\u20136038","journal-title":"Clin Cancer Res"},{"key":"351_CR48","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1152\/ajplegacy.1961.200.6.1296","volume":"200","author":"H Fleish","year":"1961","unstructured":"Fleish H, Neuman WF (1961) Mechanisms of calcification: role of collagen, polyphosphates, and phosphatase. American Journal of Physiology-Legacy Content 200:1296\u20131300","journal-title":"American Journal of Physiology-Legacy Content"},{"key":"351_CR49","doi-asserted-by":"crossref","first-page":"C1","DOI":"10.1152\/ajpcell.2001.281.1.C1","volume":"281","author":"RA Terkeltaub","year":"2001","unstructured":"Terkeltaub RA (2001) Inorganic pyrophosphate generation and disposition in pathophysiology. Am J Physiol Cell Physiol 281:C1\u2013C11","journal-title":"Am J Physiol Cell Physiol"},{"key":"351_CR50","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/BF02196199","volume":"6","author":"RG Russell","year":"1970","unstructured":"Russell RG, M\u00fchlbauer RC, Bisaz S, Williams DA, Fleisch H (1970) The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised rats. Calcif Tissue Res 6:183\u2013196","journal-title":"Calcif Tissue Res"},{"key":"351_CR51","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/BF02547219","volume":"11","author":"R Schenk","year":"1973","unstructured":"Schenk R, Merz WA, M\u00fchlbauer R, Russell RG, Fleisch H (1973) Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and dichloromethylene diphosphonate (Cl 2 MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats. Calcif Tissue Res 11:196\u2013214","journal-title":"Calcif Tissue Res"},{"key":"351_CR52","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1046\/j.1365-2141.2001.02851.x","volume":"113","author":"EV McCloskey","year":"2001","unstructured":"McCloskey EV, Dunn JA, Kanis JA, MacLennan IC, Drayson MT (2001) Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. Br J Haematol 113:1035\u20131043","journal-title":"Br J Haematol"},{"key":"351_CR53","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1046\/j.1365-2141.1998.00976.x","volume":"103","author":"MV Dhodapkar","year":"1998","unstructured":"Dhodapkar MV, Singh J, Mehta J, Fassas A, Desikan KR, Perlman M, Munshi NC, Barlogie B (1998) Anti-myeloma activity of pamidronate in vivo. Br J Haematol 103:530\u2013532","journal-title":"Br J Haematol"},{"key":"351_CR54","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.1998.16.2.593","volume":"16","author":"JR Berenson","year":"1998","unstructured":"Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs M, Blacklock H, Bell R, Simeone JF, Reitsma DJ, Heffernan M, Seaman J, Knight RD (1998) Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 16:593\u2013602","journal-title":"J Clin Oncol"},{"key":"351_CR55","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3109\/10428194.2014.924117","volume":"56","author":"KM Sanfilippo","year":"2015","unstructured":"Sanfilippo KM, Gage B, Luo S, Weilbaecher K, Tomasson M, Vij R, Colditz G, Carson K (2015) Comparative effectiveness on survival of zoledronic acid versus pamidronate in multiple myeloma. Leuk Lymphoma 56:615\u2013621","journal-title":"Leuk Lymphoma"},{"key":"351_CR56","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0","volume":"91","author":"JR Berenson","year":"2001","unstructured":"Berenson JR, Rosen LS, Howell A, Porter L, Coleman RE, Morley W, Dreicer R, Kuross SA, Lipton A, Seaman JJ (2001) Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 91:1191\u20131200","journal-title":"Cancer"},{"key":"351_CR57","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.farma.2009.09.003","volume":"34","author":"F Sierra","year":"2010","unstructured":"Sierra F, Rom\u00e1n E, Barreda C, Mole\u00f3n M, Pastor J, Navarro A (2010) Effect of pamidronate infusion time on renal function in patients with multiple myeloma. Farm Hosp 34:23\u201326","journal-title":"Farm Hosp"},{"key":"351_CR58","doi-asserted-by":"crossref","unstructured":"Raje NS, Roodman D, Willenbacher W, Shimizu K, Garcia-Sanz R, Durie BG, Zhu L, Cheng PC, Bhatta S, Terpos E (2017) Impact of denosumab (DMB) compared with zoledronic acid (ZA) on renal function in the treatment of myeloma bone disease. J Clin Oncol (supplementary; abstract 8005)","DOI":"10.1200\/JCO.2017.35.15_suppl.8005"},{"key":"351_CR59","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","volume":"29","author":"DH Henry","year":"2011","unstructured":"Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, Rv Moos, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29:1125\u20131132","journal-title":"J Clin Oncol"},{"key":"351_CR60","doi-asserted-by":"crossref","first-page":"e378","DOI":"10.1038\/bcj.2015.96","volume":"6","author":"NS Raje","year":"2016","unstructured":"Raje NS (2016) Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial. Blood Cancer J 6:e378","journal-title":"Blood Cancer J"},{"key":"351_CR61","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.ejca.2015.04.017","volume":"51","author":"IJ Diel","year":"2015","unstructured":"Diel IJ, Body J-J, Stopeck AT, Vadhan-Raj S, Spencer A, Steger G, von Moos R, Goldwasser F, Feng A, Braun A (2015) The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. Eur J Cancer 51:1467\u20131475","journal-title":"Eur J Cancer"},{"key":"351_CR62","first-page":"18","volume":"34","author":"G Lombardi","year":"2011","unstructured":"Lombardi G, Di Somma C, Rubino M, Faggiano A, Vuolo L, Guerra E, Contaldi P, Savastano S, Colao A (2011) The roles of parathyroid hormone in bone remodeling: prospects for novel therapeutics. J Endocrinol Invest 34:18\u201322","journal-title":"J Endocrinol Invest"},{"key":"351_CR63","first-page":"804182","volume":"2014","author":"MG Kang","year":"2014","unstructured":"Kang MG, Won EJ, Choi HW, Kim HR, Choi HJ, Park HR, Shin JH, Suh SP, Ryang DW, Shin MG (2014) Serum parathyroid hormone is a new potential risk factor in multiple myeloma. Biomed Res Int 2014:804182","journal-title":"Biomed Res Int"},{"key":"351_CR64","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1210\/jc.2013-4440","volume":"99","author":"BZ Leder","year":"2014","unstructured":"Leder BZ, Tsai JN, Uihlein AV, Burnett-Bowie S-AM, Zhu Y, Foley K, Lee H, Neer RM (2014) Two years of denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial. J Clin Endocrinol Metab 99:1694\u20131700","journal-title":"J Clin Endocrinol Metab"},{"key":"351_CR65","doi-asserted-by":"crossref","first-page":"e15233","DOI":"10.1371\/journal.pone.0015233","volume":"5","author":"A Pennisi","year":"2010","unstructured":"Pennisi A, Ling W, Li X, Khan S, Wang Y, Barlogie B, Shaughnessy JD Jr, Yaccoby S (2010) Consequences of daily administered parathyroid hormone on myeloma growth, bone disease, and molecular profiling of whole myelomatous bone. PLoS ONE 5:e15233","journal-title":"PLoS ONE"},{"key":"351_CR66","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1754-4505.2009.00128.x","volume":"30","author":"P Narongroeknawin","year":"2010","unstructured":"Narongroeknawin P, Danila MI, Humphreys LG Jr, Barasch A, Curtis JR (2010) Bisphosphonate-associated osteonecrosis of the jaw, with healing after teriparatide: a review of the literature and a case report. Spec Care Dentist 30:77\u201382","journal-title":"Spec Care Dentist"},{"key":"351_CR67","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1158\/1055-9965.EPI-07-2747","volume":"17","author":"GG Schwartz","year":"2008","unstructured":"Schwartz GG (2008) Prostate cancer, serum parathyroid hormone, and the progression of skeletal metastases. Cancer Epidemiol Biomarkers Prev 17:478\u2013483","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"351_CR68","doi-asserted-by":"crossref","first-page":"e3767","DOI":"10.1097\/MD.0000000000003767","volume":"95","author":"JH Wang","year":"2016","unstructured":"Wang JH (2016) Dickkopf-1 negatively regulates the expression of osteoprotegerin, a key osteoclastogenesis inhibitor, by sequestering Lrp6 in primary and metastatic lytic bone lesions. Medicine 95:e3767","journal-title":"Medicine"},{"key":"351_CR69","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1002\/jbmr.2789","volume":"31","author":"H Eda","year":"2016","unstructured":"Eda H, Santo L, Wein MN, Hu DZ, Cirstea DD, Nemani N, Tai Y-T, Raines SE, Kuhstoss SA, Munshi NC, Kronenberg HM, Raje NS (2016) Regulation of sclerostin expression in multiple myeloma by Dkk-1: a potential therapeutic strategy for myeloma bone disease. J Bone Miner Res 31:1225\u20131234","journal-title":"J Bone Miner Res"},{"key":"351_CR70","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/bjh.13056","volume":"167","author":"SP Iyer","year":"2014","unstructured":"Iyer SP, Beck JT, Stewart AK, Shah J, Kelly KR, Isaacs R, Bilic S, Sen S, Munshi NC (2014) A phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events. Br J Haematol 167:366\u2013375","journal-title":"Br J Haematol"},{"key":"351_CR71","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1080\/15476286.2015.1094600","volume":"12","author":"Y Xu","year":"2015","unstructured":"Xu Y, Chen B, George SK, Liu B (2015) Downregulation of MicroRNA-152 contributes to high expression of DKK1 in multiple myeloma. RNA Biol 12:1314\u20131322","journal-title":"RNA Biol"},{"key":"351_CR72","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.bone.2016.10.007","volume":"96","author":"J Delgado-Calle","year":"2016","unstructured":"Delgado-Calle J, Sato AY, Bellido T (2016) Role and mechanism of action of sclerostin in bone. Bone 96:29\u201337","journal-title":"Bone"},{"key":"351_CR73","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster J-Y, Zanchetta JR, Wasserman SM, Katz L, Maddox J, Yang Y-C, Libanati C, Bone HG (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370:412\u2013420","journal-title":"N Engl J Med"},{"key":"351_CR74","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1158\/0008-5472.CAN-15-1703","volume":"76","author":"J Delgado-Calle","year":"2016","unstructured":"Delgado-Calle J, Anderson J, Cregor MD, Hiasa M, Chirgwin JM, Carlesso N, Yoneda T, Mohammad KS, Plotkin LI, Roodman GD (2016) Bidirectional notch signaling and osteocyte-derived factors in the bone marrow microenvironment promote tumor cell proliferation and bone destruction in multiple myeloma. Can Res 76:1089\u20131100","journal-title":"Can Res"},{"key":"351_CR75","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3389\/fendo.2016.00067","volume":"7","author":"C Falank","year":"2016","unstructured":"Falank C, Fairfield H, Reagan MR (2016) Signaling interplay between bone marrow adipose tissue and multiple myeloma cells. Front Endocrinol (Lausanne) 7:67","journal-title":"Front Endocrinol (Lausanne)"},{"key":"351_CR76","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00223-016-0162-2","volume":"100","author":"MM McDonald","year":"2017","unstructured":"McDonald MM, Fairfield H, Falank C, Reagan MR (2017) Adipose, bone, and myeloma: contributions from the microenvironment. Calcif Tissue Int 100:433\u2013448","journal-title":"Calcif Tissue Int"},{"key":"351_CR77","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.25976","author":"H Fairfield","year":"2017","unstructured":"Fairfield H, Falank C, Harris E, Demambro V, McDonald M, Pettitt JA, Mohanty ST, Croucher P, Kramer I, Kneissel M, Rosen CJ, Reagan MR (2017) The skeletal cell-derived molecule sclerostin drives bone marrow adipogenesis. J Cell Physiol. doi: 10.1002\/jcp.25976","journal-title":"J Cell Physiol"},{"key":"351_CR78","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CAF, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532\u20131543","journal-title":"N Engl J Med"},{"key":"351_CR79","doi-asserted-by":"crossref","first-page":"18813","DOI":"10.1073\/pnas.0507417102","volume":"102","author":"G Balooch","year":"2005","unstructured":"Balooch G, Balooch M, Nalla RK, Schilling S, Filvaroff EH, Marshall GW, Marshall SJ, Ritchie RO, Derynck R, Alliston T (2005) TGF-\u03b2 regulates the mechanical properties and composition of bone matrix. Proc Natl Acad Sci USA 102:18813\u201318818","journal-title":"Proc Natl Acad Sci USA"},{"key":"351_CR80","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/nrd3810","volume":"11","author":"RJ Akhurst","year":"2012","unstructured":"Akhurst RJ, Hata A (2012) Targeting the TGF\u03b2 signalling pathway in disease. Nat Rev Drug Discov 11:790\u2013811","journal-title":"Nat Rev Drug Discov"},{"key":"351_CR81","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.3892\/ol.2017.6360","volume":"14","author":"X Liu","year":"2017","unstructured":"Liu X, Guo H, Wei Y, Cai C, Zhang B, Li J (2017) TGF-\u03b2 induces growth suppression in multiple myeloma MM.1S cells via E2F1. Oncol Lett 14:1884\u20131888","journal-title":"Oncol Lett"},{"key":"351_CR82","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.ajpath.2015.11.003","volume":"186","author":"A Lu","year":"2016","unstructured":"Lu A, Pallero MA, Lei W, Hong H, Yang Y, Suto MJ, Murphy-Ullrich JE (2016) Inhibition of transforming growth factor-\u03b2 activation diminishes tumor progression and osteolytic bone disease in mouse models of multiple myeloma. Am J Pathol 186:678\u2013690","journal-title":"Am J Pathol"},{"key":"351_CR83","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12964-015-0104-z","volume":"13","author":"OE Olsen","year":"2015","unstructured":"Olsen OE, Wader KF, Hella H, Mylin AK, Turesson I, Nesthus I, Waage A, Sundan A, Holien T (2015) Activin A inhibits BMP-signaling by binding ACVR2A and ACVR2B. Cell Commun Signal 13:27","journal-title":"Cell Commun Signal"},{"key":"351_CR84","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/bjh.12835","volume":"165","author":"KM Abdulkadyrov","year":"2014","unstructured":"Abdulkadyrov KM, Salogub GN, Khuazheva NK, Sherman ML, Laadem A, Barger R, Knight R, Srinivasan S, Terpos E (2014) Sotatercept in patients with osteolytic lesions of multiple myeloma. Br J Haematol 165:814\u2013823","journal-title":"Br J Haematol"},{"key":"351_CR85","doi-asserted-by":"crossref","first-page":"172458","DOI":"10.1155\/2015\/172458","volume":"2015","author":"F Accardi","year":"2015","unstructured":"Accardi F, Toscani D, Bolzoni M, Dalla Palma B, Aversa F, Giuliani N (2015) Mechanism of action of bortezomib and the new proteasome inhibitors on myeloma cells and the bone microenvironment: impact on myeloma-induced alterations of bone remodeling. Biomed Res Int 2015:172458","journal-title":"Biomed Res Int"},{"key":"351_CR86","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1002\/ijc.27342","volume":"131","author":"E Terpos","year":"2012","unstructured":"Terpos E, Christoulas D, Katodritou E, Bratengeier C, Gkotzamanidou M, Michalis E, Delimpasi S, Pouli A, Meletis J, Kastritis E (2012) Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy. Int J Cancer 131:1466\u20131471","journal-title":"Int J Cancer"},{"key":"351_CR87","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","volume":"389","author":"BGM Durie","year":"2017","unstructured":"Durie BGM, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, Thakuri M, Reu F, Reynolds CM, Sexton R, Orlowski RZ, Barlogie B, Dispenzieri A (2017) Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389:519\u2013527","journal-title":"Lancet"},{"issue":"1","key":"351_CR88","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/bjh.14637","volume":"178","author":"O Sezer","year":"2017","unstructured":"Sezer O, Beksac M, Hajek R, Sucak G, Cagirgan S, Linkesch W, Meltem Akay O, G\u00fclbas Z, Nahi H, Plesner T, Snowden JA, Timura\u011fao\u011flu A, Dechow T, Lang A, Tu\u011flular T, Drach J, Armbrecht G, Potamianou A, Couturier C, Olie RA, Feys C, Allietta N, Terpos E (2017) Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study. Br J Haematol 178(1):61\u201371","journal-title":"Br J Haematol"},{"key":"351_CR89","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","volume":"17","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, H\u00e1jek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosi\u00f1ol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L (2016) Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol 17:27\u201338","journal-title":"Lancet Oncol"},{"key":"351_CR90","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1158\/1078-0432.CCR-13-1657","volume":"20","author":"A Garcia-Gomez","year":"2014","unstructured":"Garcia-Gomez A, Quwaider D, Canavese M, Ocio EM, Tian Z, Blanco JF, Berger AJ, Ortiz-de-Solorzano C, Hern\u00e1ndez-Iglesias T, Martens AC (2014) Preclinical activity of the oral proteasome inhibitor MLN9708 in Myeloma bone disease. Clin Cancer Res 20:1542\u20131554","journal-title":"Clin Cancer Res"},{"key":"351_CR91","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1182\/blood.V122.21.753.753","volume":"122","author":"F-M Wang","year":"2013","unstructured":"Wang F-M, Adamik J, Rushdan S, Jin S, Ding J, Galson DL, Roodman GD (2013) Increase of Gfi1 Acetylation by HDAC Inhibitors Blocks Gfi1-Mediated Runx2 Repression in Osteoblast Precursors in Multiple Myeloma Bone Disease. Blood 122:753","journal-title":"Blood"},{"key":"351_CR92","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1158\/1541-7786.MCR-16-0242-T","volume":"15","author":"J Adamik","year":"2017","unstructured":"Adamik J, Jin S, Sun Q, Zhang P, Weiss KR, Anderson JL, Silbermann R, Roodman GD, Galson DL (2017) EZH2 or HDAC1 inhibition reverses multiple myeloma-induced epigenetic suppression of osteoblast differentiation. Mol Cancer Res 15:405\u2013417","journal-title":"Mol Cancer Res"},{"key":"351_CR93","first-page":"e9","volume":"1","author":"S Deleu","year":"2009","unstructured":"Deleu S, Menu E, Van Valckenborgh E, Van Camp B, Fraczek J, Broek IV, Rogiers V, Vanderkerken K (2009) Histone deacetylase inhibitors in multiple myeloma. Haematol Rev 1:e9","journal-title":"Haematol Rev"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00223-017-0351-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-017-0351-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-017-0351-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T00:48:46Z","timestamp":1603241326000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00223-017-0351-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,2]]},"references-count":93,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["351"],"URL":"https:\/\/doi.org\/10.1007\/s00223-017-0351-7","relation":{},"ISSN":["0171-967X","1432-0827"],"issn-type":[{"value":"0171-967X","type":"print"},{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,2]]}}}